Ragifilimab

CAS No. 2207590-51-8

Ragifilimab( —— )

Catalog No. M36831 CAS No. 2207590-51-8

Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody that targets glucocorticoid-induced TNFR-associated protein (GITR) and can be used in the study of advanced or metastatic solid tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 211 Get Quote
5MG 330 Get Quote
10MG 543 Get Quote
25MG 845 Get Quote
50MG 1150 Get Quote
100MG 1521 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Ragifilimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody that targets glucocorticoid-induced TNFR-associated protein (GITR) and can be used in the study of advanced or metastatic solid tumors.
  • Description
    Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    TNF
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2207590-51-8
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Hernandez-Guerrero T, et al: Not Ready for Prime Time. Clin Cancer Res. 2022 Sep 15;28(18):3905-3907.?
molnova catalog
related products
  • Atibuclimab

    Atibuclimab is a chimeric monoclonal antibody targeting CD14, consisting of a mouse variable region and a human IgG4 Fc region.

  • MALTOTETRAOSE

    MALTOTETRAOSE are potent inhibitors of TNF-α-induced intercellular adhesion molecule-1 (ICAM-1) expression maltotetraose may be beneficial in the suppression of early atherosclerosis development.

  • Zigakibart

    Zigakibart (BION-1301) is a humanized monoclonal antibody targeting TNFSF13 with anti-inflammatory activity for the study of immunoglobulin A nephropathy (IgAN).